Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C

被引：1
|
作者：
Griesinger, F. [1 ]
Eberhardt, W. E. E. [2 ]
Hoffknecht, P. [3 ]
Metzenmacher, M. [4 ]
Wehler, T. [5 ]
Kokowski, K. [6 ]
Alt, J. [7 ]
Schuette, W. [8 ]
Jaenicke, M. [9 ]
Fleitz, A. [9 ]
Zacharias, S. [10 ]
Hipper, A. [11 ]
Buller, M. [12 ]
Weichert, W. [13 ]
Groschek, M. [14 ]
von der Heyde, E. [15 ]
Rauh, J. [16 ]
Dechow, T. [17 ]
Sebastian, M. [18 ]
Thomas, M. [19 ]
机构：
[1] Carl von Ossietzky Univ Oldenburg, Pius Hosp, Hematol & Oncol, Oldenburg, Germany
[2] Univ Hosp Essen, Westdeutsch Tumorzentrum, Dept Med Oncol, Essen, Germany
[3] Franziskus Hosp Harderberg, Klin Thoraxonkol, Georgsmarienhutte, Germany
[4] Univ Klinikum Essen, Thorakale Onkol, Essen, Germany
[5] Lungenklin Hemer, Pneumol & Thorakale Onkol, Hemer, Germany
[6] Klinikum Bogenhausen, Klin Pneumol & Pneumol Onkol, Munich, Germany
[7] Univ Med Mainz, Dept Internal Med 3, Mainz, Germany
[8] Hosp Martha Maria Halle Doelau, Innere Med 2, Halle, Germany
[9] IOMEDICO AG, Clin Epidemiol & Hlth Econom, Freiburg, Germany
[10] IOMEDICO AG, Stat, Freiburg, Germany
[11] AIO Studien gGmbH, Project Management, Berlin, Germany
[12] AIO Studien gGmbH, Project Management, Berlin, Germany
[13] Tech Univ Munich, Inst Pathol, Inst Pathol, Munich, Germany
[14] Hamatol Onkol Stolberg, Onkol, Stolberg, Germany
[15] Gemeinschaftspraxis Strahlentherapie & Radioonkol, Onkol Schwerpunktpraxis, Hannover, Germany
[16] Praxis Innere Med, Innere Med, Witten, Germany
[17] Studienzentrum Onkol Ravensburg, Hamatol Onkol, Ravensburg, Germany
[18] Univ Hosp Frankfurt, Hamatol Onkol, Frankfurt, Germany
[19] Thoraxklin Heidelberg, Innere Med & Onkol, Heidelberg, Germany
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1678
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364P
引用
收藏
页码：S872 / S872
页数：1
相关论文
共 50 条
  • [1] Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C
    Griesinger, F.
    Eberhardt, W.
    Hoffknecht, P.
    Metzenmacher, M.
    Wehler, T.
    Kokowski, K.
    Alt, J.
    Schuette, W.
    Jaenicke, M.
    Fleitz, A.
    Zacharias, S.
    Hipper, A.
    Buller, M.
    Weichert, W.
    Groschek, M.
    von der Heyde, E.
    Rauh, J.
    Dechow, T.
    Sebastian, M.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 135 - 135
  • [2] Real-world treatment pattern and clinical outcome in Chinese NSCLC patients with KRAS G12C mutation
    Shen, L.
    Song, Z.
    Yin, Y.
    Lei, Y.
    Lu, S.
    ANNALS OF ONCOLOGY, 2024, 35
  • [3] Prevalence of KRAS p.(G12C) in stage IV non-squamous NSCLC patients in the Netherlands; a retrospective cohort study
    Garcia, B. Cajiao
    Kuijpers, C. C.
    van der Wekken, A. J.
    van Kempen, L.
    Schuuring, E.
    Willems, S.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S41 - S41
  • [4] Distant Metastasis Pattern and Baseline Clinicopathological Features from a Real-World KRAS G12C Mutant Cohort of Advanced NSCLC Patients
    Mollica, L.
    Intagliata, S.
    Bonomi, L.
    Ghilardi, L.
    Morotti, D.
    Ghirardi, G.
    Antelmi, E.
    Gianatti, A.
    Carioli, G.
    Muglia, R.
    Marra, P.
    Raimondi, F.
    Ciaravino, G.
    Di Marco, F.
    Sironi, S.
    Tondini, C. A.
    Bettini, A. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S495 - S496
  • [5] Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
    Shahnam, Adel
    Davis, Alexander
    Brown, Lauren Julia
    Sullivan, Isaac
    Lin, Kevin
    Ng, Chien
    Yeo, Nicholas
    Kong, Benjamin Y.
    Khoo, Trisha
    Warburton, Lydia
    Da Silva, Ines Pires
    Mullally, William
    Xu, Wen
    O'Byrne, Ken
    Bray, Victoria
    Pal, Abhijit
    Mersaides, Antony
    Itchins, Malinda
    Arulananda, Surein
    Nagrial, Adnan
    Kao, Steven
    Alexander, Marliese
    Lee, Chee Khoon
    Solomon, Benjamin
    John, Thomas
    LUNG CANCER, 2025, 201
  • [6] Prognostic implication of KRAS G12C mutation in a real-world KRAS mutated stage IV NSCLC cohort treated with immunotherapy in the Netherlands
    Noordhof, Anneloes L.
    Swart, Esther M.
    Damhuis, Ronald A. M.
    Hendriks, Lizza E. L.
    Kunst, Peter W. A.
    Aarts, Mieke J.
    Van Geffen, Wouter H.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [7] Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
    Noordhof, Anneloes L.
    Swart, Esther M.
    Damhuis, Ronald A. M.
    Hendriks, Lizza E. L.
    Kunst, Peter W. A.
    Aarts, Mieke J.
    van Geffen, Wouter H.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (09):
  • [8] KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
    Lim, Tony Kiat Hon
    Skoulidis, Ferdinandos
    Kerr, Keith M.
    Ahn, Myung-Ju
    Kapp, Joshua R.
    Soares, Fernando A.
    Yatabe, Yasushi
    LUNG CANCER, 2023, 184
  • [9] KRAS G12C Mutations in NSCLC: From Target to Resistance
    Addeo, Alfredo
    Banna, Giuseppe Luigi
    Friedlaender, Alex
    CANCERS, 2021, 13 (11)
  • [10] Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC
    Pinto, L. Masfarre
    Rocha, P.
    Clave, S.
    Gorro, N. Navarro
    Sanchez, I.
    Giner, M.
    Lloret, A. Corbera
    Garcia, A. Taus
    Parreira, A. S. D. F. M.
    Paricio, B. Bellosillo
    Arriola, E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S145 - S146
12345